ADRs of CSL Limited (OTCQX:CSLLY) dropped ~16% on Tuesday as Wall Street reacted to Australian biotech’s plans to lay off 15% of its workforce, announced in conjunction with its fiscal 2025 financials ...
Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence. Subscribe to TipRanks' Smart Investor Picks and see our data in action through our ...
Fintel reports that on December 8, 2025, JEFFERIES maintained coverage of CSL Limited - Depositary Receipt (OTCPK:CSLLY) with a Buy recommendation. As of December 6, 2025, the average one-year price ...
RBC Capital Markets thinks CSL is a bargain at current levels. The post Check out this CSL share price forecast for 2026.
CSL Limited has informed the market that 34,261 conditional rights (security code CSLAL) have lapsed after the performance or vesting conditions attached to them were not satisfied or became incapable ...
Jefferies analyst David Stanton maintained a Buy rating on CSL (CMXHF – Research Report) on January 17 and set a price target of A$341.00. The company’s shares closed last Friday at $163.15. Discover ...
Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of BioMarin Pharmaceutical (BMRN) and CSL Limited Sponsored ADR (CSLLY). But which of these ...
CSL Ltd.’s stock tumbled 16.88% on the news that it plans to cut 3,000 jobs and to hive off its Seqirus vaccine unit in a cost-cutting measure to save more than $500 million per year over the next ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback